Immunic | 8-K:Immunic口服IMU-856显示,乳糜泻患者中GLP-1剂量依赖性增加,临床前测试也产生相应效果
Immunic | SCHEDULE 13G/A:其他
Immunic | SCHEDULE 13G/A:其他
Immunic | SCHEDULE 13G/A:其他
Immunic | SCHEDULE 13G/A:其他
Immunic | 8-K:演示文稿
Immunic | 8-K:雇佣协议
Immunic | 4/A:持股变动声明(修正)-高管 Nash Duane
Immunic | 4:持股变动声明-高管 Vitt Daniel
Immunic | 4:持股变动声明-高管 Tardio Jason
Immunic | 4:持股变动声明-高管 Muehler Andreas
Immunic | 4:持股变动声明-高管 Nash Duane
Immunic | 4:持股变动声明-高管 Whaley Glenn
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-Avidity Partners Management LP(9.9%),Avidity Partners Management (GP) LLC(9.9%)等
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-Janus Henderson Group plc(5.7%),Janus Henderson Biotech Innovation Master Fund Ltd(5.2%)
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-RTW Investments, LP(6.1%),Roderick Wong, M.D.(6.1%)
Immunic | 4:持股变动声明-董事 Rudick Richard Alan
Immunic | SC 13G/A:超过5%持股股东披露文件(修正)-The Vanguard Group(5.21%)
Immunic | SC 13G:超过5%持股股东披露文件-Adage Capital Management, L.P.(6.21%),Robert Atchinson(6.21%)等
Immunic | 10-Q:2024财年三季报